Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03577028 · ClinicalTrials.gov registry record · Phase 1
Study of HPN424 in Patients With Advanced Prostate Cancer
A Phase 1 study, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Terminated
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT03577028 is a Phase 1 study that was terminated before completion, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 104 participants.
The verdict
NCT03577028, a Phase 1 study, was terminated before completion, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
Interventions
- BIOLOGICAL HPN424 Fixed IV 1.3 to 150 ng/kg
- BIOLOGICAL HPN424 Prime Step IV 36 ng/kg Target
- BIOLOGICAL HPN424 1 Prime Step IV 225-300 ng/kg Target
- BIOLOGICAL HPN424 2 Prime Step IV 300 ng/kg Target
- BIOLOGICAL HPN424 2 Prime Step IV 450 ng/kg Target
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-07-24 |
| Est. Completion | 2023-02-27 |
| Phase | Phase 1 |
Sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03577028
The ClinicalTrials.gov registry entry for NCT03577028 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which HPN424 Fixed IV 1.3 to 150 ng/kg is the first listed.
NCT03577028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03577028 about?
NCT03577028 is a clinical study titled "Study of HPN424 in Patients With Advanced Prostate Cancer". An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
What is the current status of trial NCT03577028?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2018-07-24. Estimated completion is 2023-02-27.
What interventions are being tested in trial NCT03577028?
The interventions under investigation include: HPN424 Fixed IV 1.3 to 150 ng/kg (BIOLOGICAL), HPN424 Prime Step IV 36 ng/kg Target (BIOLOGICAL), HPN424 1 Prime Step IV 225-300 ng/kg Target (BIOLOGICAL), HPN424 2 Prime Step IV 300 ng/kg Target (BIOLOGICAL), HPN424 2 Prime Step IV 450 ng/kg Target (BIOLOGICAL).
Who is sponsoring clinical trial NCT03577028?
This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.